{
  "docId": "019de074-ddab-749d-b286-5e01e8bcb935",
  "docSlug": "f43e68719e672319f390e5844d5bc5fe",
  "documentTitle": "Chimerix | Investor Presentation Deck | 41 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 41,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ddab-749d-b286-5e01e8bcb935/39",
  "deckHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935",
  "deckJsonHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935.json",
  "deckAnchorHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.885,
        "w": 0.453,
        "x": 0.513,
        "y": 0.109
      },
      "kind": "image",
      "text": "TEMBEXA product packaging and branding",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6d146e3-45cd-4f03-8228-52ca44b8c68d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.365,
        "w": 0.488,
        "x": 0.03,
        "y": 0.435
      },
      "kind": "list",
      "text": "$238 million received upfront at closing in Q3 2022\nUp to an additional $124 million in potential BARDA procurement milestones\n20% royalty on future U.S. gross profit with volumes above 1.7 million courses of therapy\n15% royalty of all international gross profit\nUp to an additional $12.5 million in development milestones",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f871ffc-1679-4334-a6d5-cba16f0f36cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.105,
        "w": 0.445,
        "x": 0.03,
        "y": 0.188
      },
      "kind": "paragraph",
      "text": "Emergent BioSolutions is an experienced biodefense company collaborating with government agencies to protect public health",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e2c1996-f4d8-4ef0-ba5a-7569dc4c324c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.406,
        "x": 0.297,
        "y": 0.065
      },
      "kind": "title",
      "text": "TEMBEXA® deal term summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdcde4d5-a591-46f8-b73e-8fcc14731f38",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "9c153686-7b2c-4bb5-b974-4a05beca744c",
      "evidence": "list/bullet: $238 million received upfront at closing in Q3 2022",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}